All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL HubAML HubGVhD HubLymphoma HubMDS HubMultiple Myeloma Hub

What is the role of transplant in CNL? Key considerations about timing of transplant in CNL

During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the MPN Hub was pleased to speak to Bhagirathbhai Dholaria, Vanderbilt University Medical Center, Nashville, US. We asked, What is the role of transplant in CNL? What are the key considerations about timing of transplant in CNL?

What is the role of transplant in CNL? Key considerations about timing of transplant in CNL

Dholaria begins by discussing the difficulties in obtaining data on the effectiveness of allogeneic transplants in patients with CNL. Dholaria goes on to speak about a large-scale observational study, combining data from the CIBMTR and European transplant registry, and gives an insight into disease-free and overall survival in CNL. Finally, Dholaria touches on the role of pre-transplant therapies, such as ruxolitinib, in improving patient outcomes.

 

Share: